Takeda Pharmaceutical Company (TAK) Price & Analysis

Compare

1,318 Followers

TAK Stock Chart & Stats

Day’s Range― - ―

52-Week Range$12.80 - $15.69

Previous CloseN/A

Volume1.19M

Average Volume (3M)2.83M

Market Cap

$47.03B

Enterprise Value$77.88B

Total Cash (Recent Filing)$419.18B

Total Debt (Recent Filing)$4.51T

Price to Earnings (P/E)48.4

Beta0.11

Next Earnings

Oct 30, 2025

EPS Estimate

0.16

Last Dividend Ex-Date

Mar 31, 2025

Dividend Yield4.08%

Share Statistics

EPS (TTM)0.26

Shares Outstanding3,181,967,500

10 Day Avg. Volume2,202,994

30 Day Avg. Volume2,833,473

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.66

Enterprise Value/Revenue0.02

Enterprise Value/Gross Profit0.03

Enterprise Value/Ebitda0.07

Forecast

1Y Price Target

$18.00

Price Target Upside22.12% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical TrialsBoth studies met all primary and secondary endpoints demonstrating statistically significant improvement across a broad range of NT1 symptoms compared to placebo.

Product PerformanceEntyvio continues to grow faster than the market many years into its launch, and neither biosimilar step edits nor branded competition from IL-23s seem to yet have made a major dent.

Bears Say

Pricing StrategyMFN poses a threat not just because of its direct implications, but also because of the way in which prices are determined for 340b.

Regulatory ChallengesEntyvio faces potential pricing headwinds via two government initiatives: MFN and IRA.

Takeda Pharmaceutical Company News

Takeda, Vela Transport announce medicine shipping partnership

Takeda (TAK) and Vela Transport announced their business partnership, with Takeda set to become the first biopharmaceutical company...

13d ago

TAK

Protagonist Therapeutics initiated with an Outperform at Leerink

Leerink analyst Faisal A. Khurshid initiated coverage of Protagonist Therapeutics (PTGX) with an Outperform rating and $73 price...

17d ago

JNJ

TAK

Alkermes price target lowered to $43 from $45 at Needham

Needham lowered the firm’s price target on Alkermes (ALKS) to $43 from $45 and keeps a Buy rating...

20d ago

TAK

ALKS

Harmony Biosciences price target lowered to $48 from $49 at Needham

Needham lowered the firm’s price target on Harmony Biosciences (HRMY) to $48 from $49 and keeps a Buy...

20d ago

TAK

HRMY

Alkermes price target raised to $35 from $34 at JPMorgan

JPMorgan raised the firm’s price target on Alkermes (ALKS) to $35 from $34 and keeps a Neutral rating...

20d ago

TAK

ALKS

Jefferies says stage set for Centessa to differentiate in narcolepsy

Jefferies notes that Centessa (CNTA) shares rose 18% in reaction to competitors Takeda (TAK) and Alkermes’ (ALKS) narcolepsy...

21d ago

TAK

ALKS

Takeda reports FirstLight, RadiantLight studies met all endpoints

Takeda (TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton, a potential investigational...

21d ago

TAK

Takeda announces U.S. FDA approved the sBLA for VONVENDI

Takeda (TAK) announced that the U.S. Food and Drug Administration, FDA, has approved the supplemental Biologics License Application,...

22d ago

TAK

Novavax’s COVID-19 vaccine Nuvaxovid approved in Japan

Novavax (NVAX) announced a milestone payment from Takeda (TAK) has been triggered by regulatory approval for Novavax’s COVID-19...

25d ago

TAK

NVAX

Here’s what Wall Street experts are saying about Salesforce ahead of earnings

Salesforce (CRM) is scheduled to report results of its second fiscal quarter after the market close on Wednesday,...

26d ago

CRM

NOW

Promising Phase 3 Results for Takeda’s Oveporexton Boost Buy Rating

Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co. The...

20d ago

TAK

Takeda Pharmaceutical’s Promising Narcolepsy Treatment Drives Buy Rating

Analyst Michael Nedelcovych of TD Cowen maintained a Buy rating on Takeda Pharmaceutical Company, with a price target...

21d ago

TAK

Takeda Pharmaceutical Reports Q1 2025 Earnings

Takeda Pharmaceutical Company ( ($TAK) ) has released its Q1 earnings. Here is a breakdown of the information...

2M ago

TAK

Buy Rating for Takeda Pharmaceutical Driven by Successful Phase 3 Trials of Oveporexton

Koichi Mamegano, an analyst from Bank of America Securities, maintained the Buy rating on Takeda Pharmaceutical Co. The...

3M ago

TAK

TAK FAQ

What was Takeda Pharmaceutical Company’s price range in the past 12 months?

Takeda Pharmaceutical Company lowest stock price was $12.80 and its highest was $15.69 in the past 12 months.

What is Takeda Pharmaceutical Company’s market cap?

Takeda Pharmaceutical Company’s market cap is $47.03B.

When is Takeda Pharmaceutical Company’s upcoming earnings report date?

Takeda Pharmaceutical Company’s upcoming earnings report date is Oct 30, 2025 which is in 31 days.

How were Takeda Pharmaceutical Company’s earnings last quarter?

Takeda Pharmaceutical Company released its earnings results on Jul 29, 2025. The company reported $0.264 earnings per share for the quarter, beating the consensus estimate of $0.17 by $0.094.

Is Takeda Pharmaceutical Company overvalued?

According to Wall Street analysts Takeda Pharmaceutical Company’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Takeda Pharmaceutical Company pay dividends?

Takeda Pharmaceutical Company pays a Semiannually dividend of $0.276 which represents an annual dividend yield of 4.08%. See more information on Takeda Pharmaceutical Company dividends here

What is Takeda Pharmaceutical Company’s EPS estimate?

Takeda Pharmaceutical Company’s EPS estimate is 0.16.

How many shares outstanding does Takeda Pharmaceutical Company have?

Takeda Pharmaceutical Company has 3,181,967,500 shares outstanding.

What happened to Takeda Pharmaceutical Company’s price movement after its last earnings report?

Takeda Pharmaceutical Company reported an EPS of $0.264 in its last earnings report, beating expectations of $0.17. Following the earnings report the stock price went up 0.07%.

Which hedge fund is a major shareholder of Takeda Pharmaceutical Company?

Currently, no hedge funds are holding shares in TAK

Takeda Pharmaceutical Company Stock Smart Score

Neutral

Fundamentals

Return on Equity

1.99%

Trailing 12-Months

Asset Growth

-3.89%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Takeda Pharmaceutical Company

Takeda Pharmaceutical Company Limited is a global, research and development-driven pharmaceutical company headquartered in Japan. Founded in 1781, Takeda focuses on delivering innovative medicines in key therapeutic areas such as oncology, gastroenterology, neuroscience, rare diseases, and vaccines. The company operates in various segments, including pharmaceuticals and vaccines, with a commitment to improving patient outcomes through groundbreaking research and partnerships.

Takeda Pharmaceutical Company (TAK) Earnings & Revenues

Historic Earnings Reports

TAK Company Deck

TAK Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

Takeda's earnings call highlighted strong growth in its Growth and Launch Product portfolio and progress in its R&D pipeline, supported by operational efficiencies and cash flow strength. However, the significant impact from VYVANSE generics, ENTYVIO's underperformance, and challenges in China present notable concerns.View all TAK earnings summaries

TAK Stock 12 Month Forecast

Average Price Target

$18.00

▲(22.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","13":"$13","15":"$15","17":"$17","19":"$19"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$18.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,13,15,17,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.16,15.378461538461538,15.596923076923076,15.815384615384616,16.033846153846152,16.252307692307692,16.470769230769232,16.689230769230768,16.907692307692308,17.126153846153848,17.344615384615384,17.563076923076924,17.78153846153846,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.16,15.378461538461538,15.596923076923076,15.815384615384616,16.033846153846152,16.252307692307692,16.470769230769232,16.689230769230768,16.907692307692308,17.126153846153848,17.344615384615384,17.563076923076924,17.78153846153846,{"y":18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15.16,15.378461538461538,15.596923076923076,15.815384615384616,16.033846153846152,16.252307692307692,16.470769230769232,16.689230769230768,16.907692307692308,17.126153846153848,17.344615384615384,17.563076923076924,17.78153846153846,{"y":18,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.59,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.76,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.67,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.49,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.98,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.66,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.96,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.11,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.9,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.16,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >